Nasdaq:BNGO
Bionano Genomics, Inc.
A Nasdaq-listed developer of genomic analysis instruments aimed at accelerating drug discovery through comprehensive DNA variant detection.
Key Metrics
Investment Thesis
Bull Case
Investors might consider BNGO as a high-risk, high-reward biotech play with unique intellectual property that could become a standard in structural variant detection if clinical validation proves successful. The recent reduction in net losses suggests the company is moving toward a more sustainable burn rate while maintaining a solid asset base of $76.7M in total assets.
Bear Case
The stock remains vulnerable to dilution from frequent share issuances and possesses no current path to profitability, which poses an existential threat given the limited cash reserves relative to operating expenses. Investors should avoid the stock if they cannot tolerate the risk of further significant losses that could deplete remaining equity and halt development programs.
About Bionano Genomics, Inc.
Bionano Genomics is a life science company specializing in advanced genomic analysis technologies to identify genetic variants associated with complex diseases. Serving the global pharmaceutical, biotechnology, and academic research markets, the company provides proprietary instruments for large-scale DNA mapping and sequencing solutions.
Analysis
Management Discussion
Despite a recent revenue contraction to $30.8M in 2024 compared to the prior year, the company reported an improved net loss of $112.0M versus deeper losses in previous years, suggesting potential operational stabilization. However, the negative operating cash flow of $68.9M and significant financing outflows indicate a continued heavy reliance on capital markets to fund operations and growth initiatives.
Industry Overview
The genomic analysis industry is rapidly expanding as researchers increasingly utilize advanced DNA mapping techniques to understand complex genetic disorders and accelerate personalized medicine development. While traditional sequencing dominates the market, emerging technologies like optical mapping are carving out a niche for detecting specific structural variations that other methods miss.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $27.8M | $36.1M | $30.8M |
| Cost of Revenue | $21.9M | $26.6M | $30.4M |
| Gross Profit | $5.9M | $9.6M | $380.0K |
| Operating Expenses | $137.6M | $224.8M | $104.4M |
| Operating Income | $-131.7M | $-215.2M | $-104.0M |
| R&D | $49.0M | $54.0M | $24.8M |
| G&A | $88.6M | $93.5M | $51.9M |
| Stock-Based Comp | $22.4M | $15.2M | $9.7M |
| D&A | $9.6M | $13.7M | $14.0M |
| Depreciation | $3.8M | $6.5M | $4.9M |
| Amortization | $5.8M | $7.2M | $6.6M |
| Other OpEx | $0 | $77.3M | $27.7M |
| Non-Operating Income | $986.0K | $-17.2M | $-8.0M |
| Interest Expense | $298.0K | $5.1M | — |
| Interest Income | $1.5M | $3.3M | $1.5M |
| Pre-Tax Income | $-130.7M | $-232.4M | $-112.0M |
| Income Tax | $1.9M | $62.0K | $33.0K |
| Continuing Ops | $-132.6M | $-232.5M | $-112.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-132.6M | $-232.5M | $-112.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-132.6M | $-232.5M | $-112.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $157.3M | $140.1M | $39.5M |
| Cash & Equivalents | $5.1M | $17.9M | $9.2M |
| Accounts Receivable | $7.0M | $9.3M | $4.8M |
| Inventory | $29.8M | $27.6M | $13.3M |
| Prepaid Expenses | $7.3M | $6.0M | $3.1M |
| Other Current Assets | $108.1M | $79.2M | $9.1M |
| Long-Term Assets | $150.2M | $74.3M | $37.2M |
| PP&E (Net) | $18.0M | $23.3M | $19.2M |
| Intangibles | $41.1M | $34.0M | $9.7M |
| Goodwill | $77.3M | $0 | — |
| Operating Leases | $7.2M | $5.6M | $1.8M |
| Other LT Assets | $6.5M | $11.3M | $6.5M |
| Total Assets | $307.5M | $214.4M | $76.7M |
| Current Liabilities | $35.9M | $100.0M | $37.3M |
| Accounts Payable | $12.5M | $10.4M | $7.0M |
| Current Leases | $2.3M | $2.2M | $3.0M |
| Deferred Revenue | — | $783.0K | $1.1M |
| Other Current Liab | $10.5M | $78.6M | $20.6M |
| Long-Term Liabilities | $22.2M | $18.2M | $4.0M |
| LT Operating Leases | $5.5M | $3.6M | $145.0K |
| Other LT Liab | $16.7M | $14.5M | $3.5M |
| Total Liabilities | $58.1M | $118.2M | $41.3M |
| Shareholders' Equity | $249.4M | $96.2M | $35.4M |
| Retained Earnings | $-348.7M | $-581.2M | $-693.2M |
| AOCI | $-1.1M | $23.0K | $27.0K |
| Total L&E | $307.5M | $214.4M | $76.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-132.6M | $-232.5M | $-112.0M |
| Non-Cash Adjustments | $-25.4M | $101.6M | $58.3M |
| Working Capital Changes | $33.2M | $5.7M | $-15.2M |
| Cash from Operations | $-124.8M | $-125.2M | $-68.9M |
| Cash from Investing | $82.8M | $24.2M | $73.8M |
| Cash from Financing | $23.0M | $113.8M | $-13.7M |
| FX Effect | $-38.0K | $65.0K | $-7.0K |
| Net Change in Cash | $-19.1M | $12.9M | $-8.8M |
| Beginning Cash | $24.6M | $5.5M | $18.3M |
| Ending Cash | $5.5M | $18.3M | $9.6M |
Frequently Asked Questions
How does Bionano Genomics, Inc. make money?
Revenue is primarily generated through the sale of Bionano Genomics' proprietary genome analysis systems and consumables, supported by services related to data analysis and technical support for academic and industrial research institutions.
What are the main risks for BNGO?
The company faces significant liquidity risks due to recurring net losses, a substantial retained earnings deficit, and negative cash flow from operations that relies heavily on external financing. High capital expenditure requirements for research and development alongside intense competition from established sequencing giants could erode market share if the company fails to achieve profitability quickly. Dependence on third-party manufacturing partners introduces supply chain vulnerabilities that could impact product availability.
What is BNGO's competitive advantage?
The company possesses a unique competitive edge through its patented optical mapping technology which offers superior resolution for detecting large structural variants compared to standard sequencing methods. Its integrated platform combines hardware and specialized software algorithms that streamline the workflow for identifying disease-associated genetic markers in complex genomes.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.